Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin.
Administration of exogenous insulin for the treatment of diabetes is often accompanied by the development of insulin antibodies (IA). These antibodies may affect the patient's requirement for insulin by acting as an insulin binding reservoir. The improvement of insulin purification in the 1970s and the development of human recombinant insulin both reduced the incidence of IA and their binding levels. This study investigates the parameters affecting IA frequency and binding levels in a cohort of type 1 diabetes (T1D) patients. All patients were treated with human recombinant insulin. About half of the patients had received animal insulin prior to the introduction of human recombinant insulin. We tested the IA frequency and binding level for all serum samples. IA were further analyzed for their epitope specificity comparing human and porcine insulin binding. We found that T1D patients who received animal insulin in the past show significantly higher IA binding levels as compared to patients treated exclusively with human recombinant insulin (IA binding level of 0.9 and 0.25 index, respectively, P = 0.005). T1D patients who received animal insulin in the past showed a relative bias towards porcine insulin, as compared to T1D patients who were treated with human recombinant insulin exclusively (P < 0.0001). We conclude that IA binding level and epitope specificity are biased by treatment with animal insulin. This bias remains for over 20 years after animal insulin treatment is terminated.
Oak
Shilpa
S
Department of Medicine, University of Washington, Seattle, WA, USA.
Phan
Thanh-Hien Thi
TH
Gilliam
Lisa K
LK
Hirsch
Irl B
IB
Hampe
Christiane S
CS
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000917:Antibody Formation; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011869:Radioligand Assay; D055815:Young Adult
D001323:Autoantibodies; D007004:Hypoglycemic Agents; D007328:Insulin; D007330:Insulin Antibodies